Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

@inproceedings{Reich2015EvidenceTA,
  title={Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis},
  author={K Reich and Kim Papp and Robert T Matheson and John Tu and R Bissonnette and Marc Bourcier and David Gratton and Rodion A Kunynetz and Yves P Poulin and Les A Rosoph and Georg Stingl and Wolfgang M Bauer and Janeen M Salter and Thomas M Falk and Norbert A Bl{\"o}dorn-Schlicht and Wolfgang Hueber and Ulrike Sommer and Martin M. Schumacher and Thomas Peters and Ernst Kriehuber and David M Lee and Grazyna A Wieczorek and Frank Kolbinger and Conrad C. Bleul},
  booktitle={Experimental dermatology},
  year={2015}
}
The response of psoriasis to antibodies targeting the interleukin (IL)-23/IL-17A pathway suggests a prominent role of T-helper type-17 (Th17) cells in this disease. We examined the clinical and immunological response patterns of 100 subjects with moderate-to-severe psoriasis receiving 3 different intravenous dosing regimens of the anti-IL-17A antibody secukinumab (1 × 3 mg/kg or 1 × 10 mg/kg on Day 1, or 3 × 10 mg/kg on Days 1, 15 and 29) or placebo in a phase 2 trial. Baseline biopsies… CONTINUE READING